A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multiple Center, Multiple-Dose Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Patients with Partial Onset Seizures (STAR 1)

Trial Profile

A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multiple Center, Multiple-Dose Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Patients with Partial Onset Seizures (STAR 1)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Acronyms STAR 1
  • Sponsors Zynerba Pharmaceuticals
  • Most Recent Events

    • 07 Aug 2017 Results published in a Zynerba Pharmaceuticals media release.
    • 07 Aug 2017 Primary endpoint (Composite Primary Outcome 1: To evaluate the efficacy of ZYN002 administered as a transdermal gel formulation for 12 weeks as adjunctive therapy for the treatment of partial onset seizures (POS) has not been met, according to a Zynerba Pharmaceuticals media release,
    • 01 Aug 2017 According to a Zynerba Pharmaceuticals media release, this trial completed dosing and top-line results are expected soon.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top